AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Zydus Cadila Healthcare Ltd, WO 2015102017, lorcaserin

 PATENTS, PROCESS, Uncategorized  Comments Off on Zydus Cadila Healthcare Ltd, WO 2015102017, lorcaserin
Jul 132015
 

Lorcaserin.svg

Processes for the preparation of lorcaserin

Zydus Cadila Healthcare Ltd

WO 2015102017, 09 July2015 

Applicants: CADILA HEALTHCARE LIMITED [IN/IN]; Zydus Tower, Satellite Cross Roads Ahmedabad – 380 015 Gujarat (IN)
Inventors: DWIVEDI, Shriprakash Dhar; (IN).
SHAH, Alpeshkumar Pravinchandra; (IN).
GAJJAR, Samir Rameshbhai; (IN).
KHERA, Brij; (IN)

 

 

On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes.

On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who “have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol

Useful for treating obesity.

The present invention relates to stable crystalline Form I of Iorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.

 

front page image

Stable crystalline form I of lorcaserin hydrochloride and its process of preparation are claimed.  Represents the first patenting from Cadila on lorcaserin, which was developed and launched by Arena Pharma and Eisai.

In July 2015, Newport Premium™ reported that Cadila is potentially interested in lorcaserin.

 

Lorcaserin hydrochloride is an agonist of the 5-HT2c receptor and shows effectiveness at reducing obesity in animal models and humans developed by Arena Pharmaceuticals. It is chemically represented as (R)-8-chloro-l -methyl -2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride having Formula (I) as depicted herein below.

(IA)

U.S. Patent No. 6,953,787 B2 discloses compound of Formula (I) and pharmaceutically acceptable salt, solvates or hydrates thereof and process for preparation thereof.

U.S. Patent No. 8,168,624 B2 discloses (R)-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride hemihydrate and process for its preparation. The patent also discloses crystalline Form I, Form II and Form III of (R)-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride. The crystalline Form

I and Form II are reported as anhydrous, non-solvated crystal forms. The crystalline Form III displays a dehydration feature calculated as a 3.7% weight loss which is consistent with the theoretical weight loss of 3.7% for a hemihydrate.

The patent discloses that anhydrous Form I and Form II readily converts to a hemihydrate, upon exposure to moisture. The dynamic vapor sorption (DVS) data for each of the three crystal forms reveals the hygroscopic nature of both Forms I and II, which readily adsorb moisture at relative humidity (RH) greater than about 40-60%. In addition, both Forms I and II were calculated to adsorb about 3.8% moisture between about 40 and about 80% RH which is consistent with conversion to the hemihydrate (Form III). X-ray powder diffraction (XRPD) carried out on both Forms I and II after the DVS cycle confirmed this conversion. In contrast, the DVS data in connection with Form III shows that it is substantially non-hygroscopic, adsorbing less than 0.5% water at 90% RH and the XRPD pattern showed no change in crystalline form after the DVS cycle.

International (PCT) Publication Nos. WO 2003/086306 Al, WO 2005/019179 Al, WO 2006/069363 Al, WO 2007/120517 Al, WO 2008/07011 1 Al and WO 2009/1 1 1004 Al disclose various synthetic approaches for the preparation of (R)-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine, its related salts, enantiomers, crystalline forms and intermediates.

International (PCT) Publication No. WO 2006/071740 Al discloses combination of (R)-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine with other agents. International (PCT) Publication No. WO 2012/030938 Al discloses various salts of lorcaserin with optically active acids.

U.S. PG-Pub No. US 2014/0187538 Al discloses amorphous lorcaserin hydrochloride and amorphous solid dispersion comprising lorcaserin hydrochloride and one or more pharmaceutically acceptable carriers and processes for their preparation.

International (PCT) Publication No. WO 2014/135545 Al discloses solid dispersion comprising amorphous lorcaserin hydrochloride and one or more pharmaceutically acceptable water soluble polymers.

see…..https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015102017&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription

 

Example-7: Preparation of crystalline Form I of lorcaserin hydrochloride. In a round bottom flask, 560g of methyl ethyl ketone and 40 ml water were taken and 100 g of 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine was added and stirred for 10 minutes. The reaction mass heated to 55 to 60°C and 19.3 g of. L-(+)-tartaric acid was added slowly and stirred for one to two hours. The reaction mass was further stirred at 10-15°C for an hour and the product was filtered and washed with a mixture of methyl ethyl ketone and water. The wet cake and 150 ml methyl ethyl ketone were taken in another flask and heated to 75-80°C. 20-25 ml water was, added and stirred for an hour. Further, the reaction mass was stirred for an hour at 0-5°C. The product was filtered and washed with methyl ethyl ketone.

100 g tartrate salt of 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine and 300 mL water were taken in another round bottom flask. 200 mL methylene dichloride was added and the reaction mass was cooled to 10-20°C. 17.2 g sodium hydroxide dissolved in 89 ml water was added into the reaction mass at 10-20°C. The reaction mass was stirred for an hour at 25-30°C and the layers were separated. The solvent was removed from the organic layer under vacuum and then 100 mL ethyl acetate was added into that and distilled out. Further, 100 mL ethyl acetate was added and stirred for 15 minutes. The reaction mass was filtered through a hyflow bed and the filtrate was treated with dry HC1 gas till a pH of 1.5 to 2.5 was obtained at 0-10°C and it was stirred for about 30 minutes to an hour. The product was then filtered and washed with ethyl acetate and then dried in a vacuum oven at 50°C to 55°C for 2 hours. The product was further dried at 90°C to 110°C for 20 hours to obtain crystalline Form I of lorcaserin hydrochloride. Yield: 87.5-98.6 %.

Example-8: Preparation of crystalline Form I of lorcaserin hydrochloride

In a round bottom flask, 2.20 g lorcaserin, 30 mL methylene chloride, 17.4 mL of 1M HCI in ether were added and the mixture was stirred for 5-15 minutes at room temperature. The solvent was removed under reduced pressure to give a white solid. This solid was again dissolved in 30 ml methylene chloride, 17.4 mL of 1M HCI solution and stirred for 5-15 minutes at room temperature. The solvent was removed under reduced pressure to give lorcaserin hydrochloride. The product was dried in a vacuum oven at 50°C to 55°C for 2 hours. The product was further dried at 90°C to 110°C for 20 hours to obtain crystalline Form I of lorcaserin hydrochloride.

Example-9: Preparation of crystalline Form I lorcaserin hydrochloride

50 g of lorcaserin hydrochloride hemihydrate and 50 g of hydroxypropylmethyl cellulose (HPMC) 3CPC were mixed in a blender at 25°C to 35°C. The mixture was mixed for 30 minutes and unloaded. The solid thus obtained was dried in a vacuum oven at 50°C to 55°C for 2 hours. The product was further dried at 90°C to 110°C for 20 hours to obtain crystalline Form I of lorcaserin hydrochloride.

Pankaj R. Patel (right), Chairman and Managing Director,

New Horizons Pluto Flyby

/////////

Share

Trimyristin

 PROCESS, spectroscopy  Comments Off on Trimyristin
Jul 122015
 

Trimyristin

Trimyristin

Trimyristin is an ester with the chemical formula C45H86O6. It is a saturated fat which is the triglyceride of myristic acid. Trimyristin is a white to yellowish-gray solid that is insoluble in water, but soluble in ethanol, benzene, chloroform, dichloromethane, and ether.

 

Name Trimyristin
Synonyms Glycerol trimyristate
Name in Chemical Abstracts Tetradecanoic acid, 1,2,3-propanetriyl ester
CAS No 555-45-3
EINECS No 209-099-7
Molecular formula C45H86O6
Molecular mass 723.18
SMILES code CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC
Nutmeg
reacts to
Trimyristin

TRIMYRISTIN.png

Occurrence

Trimyristin is found naturally in many vegetable fats and oils.

Isolation from nutmeg

Seed of nutmeg contains trimyristin

The isolation of trimyristin from powdered nutmeg is a common introductory-level college organic chemistry experiment. It is an uncommonly simple natural product extraction because nutmeg oil generally consists of over eighty percent trimyristin. Trimyristin makes up between 20-25% of the overall mass of dried, ground nutmeg. Separation is generally carried out by steam distillation and purification uses extraction from ether followed by distillation or rotary evaporation to remove the volatile solvent. The extraction of trimyristin can also be done with diethyl ether at room temperature, due to its high solubility in the ether. The experiment is frequently included in curricula, both for its relative ease and to provide instruction in these techniques.

1H-NMR

1H NMR

1H-NMR: Trimyristin
300 MHz, CDCl3
delta [ppm] mult. atoms assignment
0.90 m 9 H 14-H (CH3)
1.2-1.4 m 60 H 4-13-H (CH2)
1.5-1.7 m 6 H 3-H
2.33 m 6 H 2-H
4.16 dd 2 H glycerol-C1-Ha
4.31 dd 2 H glycerol-C1-Hb
5.28 m 1 H glycerol-C2-H
7.26 CHCl3
2.11 acetone (impurity)

Isolation of trimyristin from nutmeg

Reaction type: isolation of natural products
Substance classes: carboxylic acid ester, triglyceride, natural product
Techniques: extracting with Soxhlet extractor, evaporating with rotary evaporator, recrystallizing, filtering, heating under reflux, heating with oil bath, stirring with magnetic stir bar
Degree of difficulty: Easy
Batch scale: 25 g Nutmeg

Reaction……….http://kriemhild.uft.uni-bremen.de/nop/en/instructions/pdf/1021_en.pdf

The reaction apparatus consists of a 250 mL round-bottom flask with a magnetic stir bar and a 100 mL soxhlet extraction unit with a reflux condenser. 25 g of finely ground nutmeg are placed into the extraction sleeve and covered with a little glass wool. 150 mL tert-butyl methyl ether are placed into the flask and whilst stirring, the solvent is heated to reflux until the solvent leaving the extraction sleeve is colourless (approximately 5 hours).

Work up

The solvent is evaporated with a final pressure of 20 hPa. The flask containing the residue is cooled in an ice bath or the refrigerator until the contents has crystallized to a thick slurry.

Crude product yield: 12 g;

The crude product is recrystallized from the minimum amount of ethanol. Prior to filtering the crystals, the flask is placed into the refrigerator for at least 30 minutes. The crystalline slurry is filtered and the product is dried in an evacuated desiccator over silica gel. Should the crystals not be colourless after the first recrystallization, a second recrystallization is carried out.

Yield: 6.5 g; melting point 54-55 °C;

Duration of the experiment

Without recrystallization 6 hours

Where can I stop the experiment?

Before and after the evaporation of the solvent

Recycling

The evaporated tert-butyl methyl ether and the evaporated ethanol from the mother liquor are collected and redistilled.

Suggestions for waste disposal

Waste Disposal
residue from mother liquor domestic waste
residue from extraction domestic waste

Operating scheme

Operating scheme

Substances required

Batch scale: 25 g Nutmeg
Educts Amount Risk Safety
Nutmeg
25 g R S
Solvents Amount Risk Safety
Ethanol
F F
~ 150 mL R 11 S 2-7-16
tert-Butyl methyl ether
F F Xi Xi
150 mL R 11-38 S 2-9-16-24
Others Amount Risk Safety
Iodine
Xn Xn N N
0.1 g R 20/21-50 S 2-23.2-23.4-25-61
Solvents for analysis Amount Risk Safety
Cyclohexane
F F Xn Xn N N
? R 11-38-50/53-65-67 S 2-9-16-33-60-61-62
Acetic acid ethyl ester
F F Xi Xi
? R 11-36-66-67 S 2-16-26-33

Substances produced

Batch scale: 25 g Nutmeg
Products Amount Risk Safety
Trimyristin
6.5 g R S

Equipment

Batch scale: 25 g Nutmeg
round bottom flask 250 mL round bottom flask 250 mL Soxhlet extractor 100 mL Soxhlet extractor 100 mL
glass wool glass wool extraction cone extraction cone
heatable magnetic stirrer with magnetic stir bar heatable magnetic stirrer with magnetic stir bar oil bath oil bath
reflux condenser reflux condenser rotary evaporator rotary evaporator
ice bath ice bath exsiccator with drying agent exsiccator with drying agent
suction filter suction filter suction flask suction flask

Simple evaluation indices

Batch scale: 25 g Nutmeg
Atom economy not defined
Yield not defined
Target product mass 6.5 g
Sum of input masses 250 g
Mass efficiency 26 mg/g
Mass index 39 g input / g product
E factor 38 g waste / g product
Energy input 1500 kJ
Energy efficiency 4.3 mg/kJ

Chromatogram

crude product chromatogram

TLC: crude product
TLC layer Polygram SilG/UV precoated TLC layer; 0.2 mm; silica gel; Macherey & Nagel
mobile phase cyclohexane / EtOAc = 95 : 5
staining reagent Vaughn’s reagent or iodine vapor
Rf (product) 0.51

13C-NMR

13C NMR

13C-NMR: Trimyristin
300 MHz, CDCl3
delta [ppm] assignment
14.08 C14
22.66 C13
24.85-24.89 C3, C17
29.06-31.90 C4-C12
34.04-34.2 C2
62.08 glycerol-C1
68.85 glycerol-C2
172.85 C15
173.26 C1
76.5-77.5 CDCl3

IR

IR

IR: Trimyristin
[KBr, T%, cm-1]
[cm-1] assignment
2950-2850 aliph. C-H valence
1730 C=O valence, ester

 

Trimyristin[1]
Skeletal formula of trimyristin
Ball-and-stick model of trimyristin
Space-filling model of trimyristin
Names
IUPAC name

1,3-Di(tetradecanoyloxy)propan-2-yl tetradecanoate
Other names

Glyceryl trimyristate; Glycerol tritetradecanoate;[2] 1,2,3-Tritetradecanoylglycerol[3]
Identifiers
555-45-3 Yes
ChemSpider 10675 
EC number 209-099-7
Jmol-3D images Image
PubChem 11148
UNII 18L31PSR28 Yes
Properties
C45H86O6
Molar mass 723.18 g·mol−1
Appearance White-yellowish gray solid
Odor Nutmeg-like
Density 0.862 g/cm3 (20 °C)[4]
0.8848 g/cm3 (60 °C)[2]
Melting point 56–57 °C (133–135 °F; 329–330 K)
Boiling point 311 °C (592 °F; 584 K)
Solubility Slighty soluble in alcohol, ligroin
Soluble in (C2H5)2O, acetone, C6H6,[2] CH2Cl2, CHCl3
1.4428 (60 °C)[2]
Structure
Triclinic (β-form)[3]
P1 (β-form)[3]
a = 12.0626 Å, b = 41.714 Å, c = 5.4588 Å (β-form)[3]
α = 73.888°, β = 100.408°, γ = 118.274°
Thermochemistry
1013.6 J/mol·K (β-form, 261.9 K)
1555.2 J/mol·K (331.5 K)[5][6]
1246 J/mol·K (liquid)[6]
−2355 kJ/mol[6]
27643.7 kJ/mol[6]
Hazards
NFPA 704
Flammability code 0: Will not burn. E.g., water Health code 1: Exposure would cause irritation but only minor residual injury. E.g., turpentine Reactivity code 0: Normally stable, even under fire exposure conditions, and is not reactive with water. E.g., liquid nitrogen Special hazards (white): no code

NFPA 704 four-colored diamond

Flash point > 110 °C (230 °F; 383 K)[7]
421.1 °C (790.0 °F; 694.2 K)[7]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
    1. References

    2. Merck Index, 11th Edition, 9638.
    3. Lide, David R., ed. (2009). CRC Handbook of Chemistry and Physics (90th ed.). Boca Raton, Florida: CRC Press. ISBN 978-1-4200-9084-0.
    4. Van Langevelde, A.; Peschar, R.; Schenk, H. (2001). “Structure of β-trimyristin and β-tristearin from high-resolution X-ray powder diffraction data”. Acta Crystallographica Section B Structural Science 57 (3): 372. doi:10.1107/S0108768100019121. edit
    5. Sharma, Someshower Dutt; Kitano, Hiroaki; Sagara, Kazunobu (2004). “Phase Change Materials for Low Temperature Solar Thermal Applications” (PDF). http://www.eng.mie-u.ac.jp. Mie University. Retrieved 2014-06-19.
    6. Charbonnet, G. H.; Singleton, W. S. (1947). “Thermal properties of fats and oils”. Journal of the American Oil Chemists Society 24 (5): 140. doi:10.1007/BF02643296. edit
    7. Trimyristin in Linstrom, P.J.; Mallard, W.G. (eds.) NIST Chemistry WebBook, NIST Standard Reference Database Number 69. National Institute of Standards and Technology, Gaithersburg MD. http://webbook.nist.gov (retrieved 2014-06-19)

“MSDS of Trimyristin”

      .

http://www.fishersci.ca

      . Fisher Scientific. Retrieved 2014-06-19.

 

 

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK

Join me on twitterFollow amcrasto on Twitter
Join me on google plus Googleplus

 amcrasto@gmail.com

09b37-misc2b027LIONEL MY SON

He was only in first standard in school when I was hit by a deadly one in a million spine stroke called acute transverse mylitis, it made me 90% paralysed and bound to a wheel chair, Now I keep him as my source of inspiration and helping millions, thanks to millions of my readers who keep me going and help me to keep my son happy

…………

Share

Sofosbuvir new patent…WO 2015097605, Mylan

 PATENTS, PROCESS  Comments Off on Sofosbuvir new patent…WO 2015097605, Mylan
Jul 102015
 

Sofosbuvir.svg

WO 2015097605

Mylan Laboratories Ltd.

Process for the preparation of sofosbuvir

02 July 2015

The present disclosure relates to processes for the preparation of sofosbuvir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of sofosbuvir.

Kaushik, Vipin Kumar; Vakiti, Srinivas; Ravi, Vijaya Krishna; Tirumalaraju, Bhavanisankar

Nucleoside phosphoramidates are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

Sofosbuvir (PSI-7977) is a nucleotide analog inhibitor of HCV NS5B polymerase, which is developed by Pharmasset and used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.

SOVALDI® tablets contain sofosbuvir, which is chemically named as (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)-(phenoxy)phosphorylamino) propanoate and is represented by the following chemical structure:

Formula-1

Sofosbuvir and a process for the preparation are disclosed in U.S. Patent No. 7,964,580 B2 and PCT Publication No. WO 2008/121634 A2, which are hereby incorporated by reference.

The present disclosure provides a novel process for the preparation of sofosbuvir or its pharmaceutically acceptable salts that employs novel intermediates.

 
सुकून उतना ही देना प्रभू, जितने से
जिंदगी चल जाये।
औकात बस इतनी देना,
कि औरों का भला हो जाये।

 

 

SUMMARY OF THE DISCLOSURE

A first aspect of the present disclosure is to provide a process for the preparation of sofosbuvir or its pharmaceutically acceptable salts.

In one embodiment, the present disclosure provides a process for the preparation of sofosbuvir or its pharmaceutically acceptable salts that includes the steps of:

a) reacting the compound of formula 4 with a compound of formula 5 to get a compound of formula 3;


4

b) hydrolyzing the compound of formula 3 to get a compound of formula 2; and

3 2

c) optionally deprotecting the compound of formula 2 to get sofosbuvir of formula 1 or its pharmaceutically acceptable salts.

1

2

wherein R is hydrogen or any hydroxy protecting group and X is a leaving group such as tosylate, camphorsulfonate, mesylate, trifluoroacetate, trifluorosulfonate, an aryloxide, heteroaryl oxide or an aryloxide or heteroaryl oxide substituted with at least one electron-withdrawing group.

In another embodiment, the present disclosure provides a novel intermediate of formula 3a.

 

In an additional embodiment, the present disclosure provides a crystalline compound of formula 3a, which is characterized by a powdered X-ray diffraction pattern as shown in Figure 1.

In September 2014, Gilead entered into non-exclusive licensing agreements with various generic companies (including Mylan) to manufacture and supply generic sofosbuvir. In April 2015, Mylan launched its generic version of the drug as MyHep, in India

 

scheme-II.

Sofosbuvir

Scheme-II

In another embodiment the present disclosure provides a process for the preparation of sofosbuvir as shown in below scheme-Ill.

 

Example 3: Preparation of sofosbuvir (formula 1).

N-Benzoyl Sofosbuvir (6 g) was added to 70% w/w aqueous acetic acid (90 mL) and the contents were stirred at 90-95 °C. After completion of the reaction, which was monitored by qualitative HPLC, the reaction mass was cooled to ambient temperature, diluted with water and filtered through a Hyflo filter. Thereafter, obtained filtrate was extracted with ethyl acetate which was further washed with ~4%w/w aqueous hydrochloric acid followed by ~9%w/w aqueous sodium carbonate solution. Finally, the ethyl acetate layer was washed with water and dried. The dried layer was concentrated under reduced pressure at 60-65 °C. Thereafter, the concentrated mass was dissolved in a mixture of 5% isopropanol in methylene dichloride and isopropyl ether was added to precipitate the product. After stirring at 0-5 °C for 2 hours, the product was filtered, washed with methylene dichloride/isopropyl ether mixture, which was recrystallized with methylene dichloride/isopropyl ether mixture to yield sofosbuvir as white crystals (3 g)……https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015097605&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription

Mylan launches Sovaldi tablets in India

Sovaldi is indicated for the treatment of chronic hepatitis-C infection as a component of a combination antiviral treatment

Pharma giant Mylan NV today said its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences’ Sovaldi (sofosbuvir 400mg tablets) in the country.
Sovaldi is indicated for the treatment of chronic hepatitis-C infection as a component of a combination antiviral treatment.
It is estimated that around 12 million people are chronically infected with hepatitis-C in India, Mylan said in a release.
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.
Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.
“We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India,” Malik said.
Gregg Alton, Executive Vice-President, Corporate and Medical Affairs, Gilead Sciences said it makes an important milestone in the company’s ongoing effort to make its hepatitis-C medicines accessible to as many patients, in as many places, as quickly as possible.Sovaldi is sold by Mylan’s dedicated sales force as part of its Hepato Care segment.

,,,,,,,,,,

 

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK

Join me on twitterFollow amcrasto on Twitter
Join me on google plus Googleplus

 amcrasto@gmail.com

09b37-misc2b027LIONEL MY SON
He was only in first standard in school when I was hit by a deadly one in a million spine stroke called acute transverse mylitis, it made me 90% paralysed and bound to a wheel chair, Now I keep him as my source of inspiration and helping millions, thanks to millions of my readers who keep me going and help me to keep my son happy
सुकून उतना ही देना प्रभू, जितने से
जिंदगी चल जाये।
औकात बस इतनी देना,
कि औरों का भला हो जाये।
Share

UGI PRODUCT

 PROCESS, spectroscopy, SYNTHESIS, Uncategorized  Comments Off on UGI PRODUCT
Jul 052015
 

 Exp148-iii.JPG

To synthesize a Ugi adduct from phenanthrene-9-carboxaldehyde, 1-heptylamine, tert-butylisocyanide and crotonic acid in methanol using Ugi 4CR

Procedure

To a one gram vial, charged with methanol (1mL) heptylamine, phenanthrene-9-carboxaldehyde, crotonic acid and tert-butyl isonitrile (0.5mmol each) was added in that order. After each addition, the resulting solution was vortexed for 15 seconds (or more) and confirmed that a homogeneous solution had been obtained. The vial was capped tight and left at room temperature for 3 days. The solution formed solid upon moving it to another spot. The obtained solid was washed with methanol (3 x 500uL), centrifuged each time to obtain a white residue. The wet product was set under a high vac to remove the solvent.

Characterization : White powder; M.pt~ 179-181C; H-NMR (external image delta.gif ppm, CDCl3) 0.30 (m, 1H), 0.54-0.95 (m, 10H), 1.05-1.2 (m, 1H ), 1.39 (s, 9H), 1.89 (d, 3H J 6.8Hz), 2.86 (bs, 1H), 3.28-3.60 (m 2H ), 5.79 (s,1H), 6.24 (d,1H J 15Hz), 6.87 (s 1H), 7.0-7.15 (m 1H), 7.56-7.76 (m 4H), 7.88 (d 1H J 7.85 Hz), 7.92-8.04 (m 2H), 8.68 (d 1H J 8.25 Hz), 8.73 (d 1H J 8.25Hz); 13C NMR (external image delta.gif ppm, CDCl3) 13.8, 18.2, 22.1, 26.2, 27.9, 28.6, 29.9, 31.0, 45.5, 51.7, 57.8, 122.0, 122.4, 123.1, 124.1, 126.8, 126.9, 127.43, 127.48, 128.9, 129.15, 129.16, 130.3, 130.47, 130.9, 131.0, 142.7, 166.9, 169.9; IR (KBr, 1/cm): v=3315, 3080, 2926, 2855, 1663, 1614, 1452, 1419, 748, 728; HRMS m/z calcd for C31 H40 N2 O2 : 495.298748 [M+Na]; found 495.2997.

Characterization amount: 118.5 mg

m.p. 179-181C
HNMR(50mg in 700uL CDCl3)
CNMR(50mg in 700uL CDCl3)
HRMS (FAB) [M+Na]
Nominal Mass (FAB) [M+H]
Nominal Mass (FAB) [M+Na]
IR (KBr)

Conclusion

A Ugi product was successfully synthesized in 50% yield.

Share
Jan 312015
 

 

Image: Manufacturing process for synthetic pharmaceuticals
Manufacturing process for chemical synthesis pharmaceuticals

 

There are two main types of processes used to manufacture pharmaceuticals: chemical synthesis based on chemical reactions, and bioprocessing based on the ability of microorganisms and cells to produce useful substances.

Chemical synthesis can be used to produce pharmaceutical products with relatively low molecular weights in large volumes in short timespans. In addition, various chemical modifications can be applied to enhance the activity of the substance produced.
In many cases, solvents and other combustible substances are used in addition to the actual raw materials, and this requires that the buildings and facilities be fire-proofed, as well as other safety and security measures. Also, in many cases, corrosive fluids are involved, requiring the use of glass linings or other anti-corrosive measures.

The manufacturing processes often entail crystallization and crystal separation, with many processes needed for transport and insertion of solids. In general, pharmaceutical plants produce many different products, and production lines must be kept separate from one another to prevent cross-contamination of products.

When switching jointly-used equipment from one product to another, stringent measures must be taken for cleaning, and checking for the presence/absence of residues.

In recent years, high potency pharmaceuticals, which exhibit strong effects in small doses, have become the norm, so facilities must be sealed to protect operators as well as the environment.

see    http://www.nature.com/nrd/journal/v2/n8/full/nrd1154.html

In the past, process R&D — which is responsible for producing candidate drugs in the required quantity and of the requisite quality — has had a low profile, and many people outside the field remain unaware of the challenges involved. However, in recent years, the increasing pressure to achieve shorter times to market, the demand for considerable quantities of candidate drugs early in development, and the higher structural complexity — and therefore greater cost — of the target compounds, have increased awareness of the importance of process R&D.

Here, I discuss the role of process R&D, using a range of real-life examples, with the aim of facilitating integration with other parts of the drug discovery pipeline….http://www.nature.com/nrd/journal/v2/n8/full/nrd1154.html

 

BIOPHARMACEUTICALS

external image nrd1523-f1.jpgPIC CREDIT TO……….. http://gsk.wiki.hci.edu.sg/Pharmaceutical+Science

The WHO Prequalification of Medicines Programme (PQP) facilitates access to quality medicines through assessment of products and inspection of manufacturing sites. Since good-quality active pharmaceutical ingredients (APIs) are vital to the production of good-quality medicines, PQP has started a pilot project to prequalify APIs.

WHO-prequalified APIs are listed on the WHO List of Prequalified Active Pharmaceutical Ingredients. The list provides United Nations agencies, national medicines regulatory authorities (NMRAs) and others with information on APIs that have been found to meet WHO-recommended quality standards.  It is believed that identification of sources of good-quality APIs will facilitate the manufacture of good-quality finished pharmaceutical products (FPP) that are needed for procurement by UN agencies and disease treatment programmes.

Details of the API prequalification procedure are available in the WHO Technical Report Series TRS953, Annex 4.  Key elements of this document are given below.

What is API prequalification?

API prequalification provides an assurance that the API concerned is of good quality and manufactured in accordance with WHO Good Manufacturing Practices (GMP).

API prequalification consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements.

Prequalification of an API is made with specific reference to the manufacturing details and quality controls described in the APIMF submitted for assessment.  Therefore, for each prequalified API, the relevant APIMF version number will be included in the WHO List of Prequalified Active Pharmaceutical Ingredients.

Steps in the process

 

The WHO prequalification procedure for medicines and active pharmaceutical ingredients

 

Initially, an application is screened to determine whether it is covered by the relevant expression of interest (EOI).  It is also screened for completeness; in particular, the formatting  of the submitted APIMFs is reviewed. Once the application has been accepted, a WHO reference number is assigned to it.

A team of assessors then reviews the submitted APIMF, primarily at bimonthly meetings in Copenhagen. Invariably, assessors raise questions during assessment of the APIMF that require revision of the information submitted and/or provision of additional information, and/or replacement of certain sections within the APIMF. Applicants are contacted to resolve any issues raised by the assessors.

It is important that any prequalified API can be unambiguously identified with a specific APIMF. Therefore, once any and all issues regarding its production have been resolved, the applicant will be asked to submit an updated APIMF that incorporates any changes made during assessment. The version number of the revised and up-to-date APIMF will be included on the WHO List of Prequalified Active Pharmaceutical Ingredients, to serve as a reference regarding the production and quality control of that API.

For APIMFs that have already been accepted in conjunction with the prequalification of an FPP, full assessment is generally not required. Such APIMFs are reviewed only for key information and conformity with administrative requirements. Nonetheless, a request for further information may be made, to ensure that the APIMF meets all current norms and standards; PQP reserves the right to do so.

An assessment is also undertaken of WHO GMP compliance at the intended site(s) of API manufacture. Depending on the evidence of GMP supplied by the applicant, this may necessitate on-site inspection by WHO. If a WHO inspection is conducted and the site is found to be WHO GMP-compliant, the API will be recommended for prequalification. Additionally, a WHO Public Inspection Report (WHOPIR) will be published on the PQP web site.

When the APIMF and the standard of GMP at the intended manufacturing site(s) have each been found to be satisfactory, the API is prequalified and listed on the WHO List of Prequalified Active Pharmaceutical Ingredients.

The successful applicant will also be issued a WHO Confirmation of Active Pharmaceutical Ingredient Prequalification document.  This document contains the accepted active ingredient specifications and copies of the assay and related substances test methodology. This document may be provided by the API manufacturers to interested parties at their discretion.

 

Maintenance of API prequalification status

Applicants are required to communicate to WHO any changes that have been made to the production and control of a WHO-prequalified API. This can either be in the form of an amendment, or as a newly-issued version of the APIMF. It is the applicant’s responsibility to provide WHO with the appropriate documentation (referring to relevant parts of the dossier), to prove that any intended or implemented change will not have or has not had a negative impact on the quality of the prequalified API. This may necessitate the updating of the information published on the WHO List of Prequalified Active Pharmaceutical Ingredients.

The decision to prequalify an API is based upon information available to WHO at that time, i.e. information in the submitted APIMF, and on the status of GMP at the facilities used in the manufacture and control of the API. The decision to prequalify an API is subject to change, should new information become available to WHO. For example, if serious safety and/or quality concerns arise in relation to a prequalified API, WHO may suspend the API until the investigative results have been evaluated by WHO and the issues resolved, or delist the API in the case of issues that are not resolved to WHO’s satisfaction.

CASE STUDY

READ………http://www.nature.com/nrd/journal/v2/n8/box/nrd1154_BX1.html

 

 

 

Upon Fermentation Penicillin is put through a Recovery Process to obtain its crystallized form, Which can than be dissolved in saline and injected into a patient for treatment.

Recovery Process:

1. Broth Filtration :

  • The main objective is to remove any microbial cells and any large solid particles such as, cell fragments, soluble and insoluble medium components, other metabolic products, Intact micro-organims.
  • During the filtration the micro-organisms are captured in a concentrated cake, which looks like sand, sludge or paste.
  • There are many factors that influence the type of filtration to be used:
    1. Viscosity.
    2. Density of filtrate.
    3. Solid liquid ratio.
    4. Size and shape of particles.
    5. Scale of operation.
    6. Need for aseptic conditions.
    7. Need for batch or continuous operation.
    8. Need for pressure or vacuum suction to ensure an sufficient for rate for liquid.
  • The rotary type is the most often used filtration, its features include:
    1. The Filter Drum: Cylindrical, hollow drum which carries the filter cloth. On the inside it is segmented into rows to which a vacuum can be applied or shut off in sequence as the drum slowly revolves.
    2. Trough: Filter is partially immersed in through which contains the penicillin broth. The trough is sometimes fitted with an agitator to maintain solids in suspension.
    3. Discharge Nodes: Filter cakes are produced from the filtration of to penicillin broth. Because of this a node is devised to scrap off the cake after filtration. When this happens the vacuum is broken.
  • The filter drum, partially submerged in the trough of broth, rotates slowly. Filtrateand washings are kept separate by the segments in the drum. The liquid is drawn throughthe filter and a cake of solids builds up on the outer surface. Inside the drum, the filtrate is moves from the end of the cylindrical drum onto a storage tank. As our penicillin cellsmove from the broth, the vacuum is used to remove as much moisture as possible fromthe cake, and to hold the cake on the drum. The section at the node/knife, which scrapes off the filtrate can get air pressure to burst out, helping contact with the node.

2. Filtrate cooled:

  • From filtration, the penicillin rich solution is cooled tp 5°C.
  • This helps reduce enzyme and chemical degradation during the 4th step; solvent extraction.

3. Further Filtration:

  • More filtration is done with rotary filtration method.

4. Extraction of Penicillin with solvent:

  • This method is carried out under the basis that the extraction agent and the liquid in which the extract is dissolved cannot be mixed.
  • Solvent extraction is suitable for the recovery of penicillin because of its operation at low temperatures, greater selectivity and is less expensive compared to distillation, evaporation and membrane technology.
  • A Podbielniak Centrifugal Contractor is used for this method.

5. Carbon Treatment:

  • The penicillin rich solution is then treated with 0.25-5% activated carbon to remove pigments and impurities.
  • Activated carbon is an amorphous solid that absorbs molecules from the liquid phase through its’ highly developed internal pore structure.
  • It is obtained in powered, pelleted or granular form and is produced from coal, wood and coconut shells.

6. Transfer Back to Aqueous state:

  • Using a Podbielniak Centrifugal Contractor, like the one used in solvent extraction, the penicillin rich solvent is passed into a fresh aqueous phase.
  • This is done in the presence of Potassium or Sodium Hydroxide to bring the pH back to 5.0-7.5, creating the penicillin salt.

7. Solvent Recovery:

  • The penicillin solvent is usually recovered by distillation.
  • Distillation is carried out in three phases:
    1. Evaporation.
    2. Vapour-liquid seperation in a column.
    3. Condensation of vapour.
  • Firstly the solvent is vaporised from the solution, then the low boiling volatile components are separated from the less volatile components in a column, and finally condensation is used to recover the volatile solvent fraction.
  • Solvent recovery is an important process, as solvent is a major expense in the penicillin extraction process.

8. Crystallisation:

  • Crystallisation is essentially a polishing step that yields a highly pure product and is done through phase separation from a liquid to a solid.
  • To begin the process a supersaturated solution, where there are more dissolved solids in the solvent than can ordinarily be accommodated at that temperature, must be obtained through cooling, drowning, solvent evaporation, or by chemical reaction.
  • The two main methods are Cooling and Drowning.
  • Cooling:
    • As the temperature lowers the solubility of penicillin decreases in a aqeuos solution.
    • Thus as the cooling takes place, the saturation increases till it reaches supersaturation and than on to crystallisation.
  • Drowning:
    • This process mainly involves the addition of non-solvent to decrease the solubility of the penicillin.
    • This than leads to saturation than to super saturation and finally to crystallisation.
  • Crystallisation process after supersaturation has two phases:
    1. Phase 1 Primary Nucleation:
      • This phase is mainly the growth of new crystals.
      • The spontaneous crystal formation and “crashing out” of many nuclei are observed from the solution.
    2. Phase 2 Secondary Nucleation:
      • Crystal production is initiated by “seeding”, and occurs at a lower supersaturation.
      • Seeding involves the addition of small crystals to a solution in a metastable area, which results in interactions between existing crystals, and crystal contact with the walls of the crystalliser.
      • The crystals will grow on those crystals until the concentration of the solution reaches solubility equilibrium.
  • Batch crystallisation is the most the most used method for polishing penicillin G. Batch crystallisers simply consist of tanks with stirrers and are sometimes baffled. They are slowly cooled to produce supersaturation. Seeding causes nucleation and growth is encouraged by further cooling until the desired crystals are obtained.
  • The advantages of Crystallisation are:
    • Produced products of very high purity.
    • Improves products appearance.
    • And has a low energy input.
  • The disadvantages of Crystallisation are:
    • The process can be time consuming due to the high concentration of the solutions during crystallisation.
    • It can also be profoundly affected by trace impurities.
    • Batch crystallisation can often give poor quality, nonuniform product.

9. Crystal washing:

  • Even though the penicillin crystals are pure in nature, adsorption and capillary attraction can cause impurities from its mother liquor on their surfaces and within the voids of the particulate mass.
  • Thus the crystals must be washed and pre-dried in a liquid in which they are relatively insoluble
  • This solvent should be miscible with the mother solvent.
  • For this purpose anhydrous lpropanol, n-butanol or another volatile solvent is used.

10. Drying of Crystals:

  • Drying stabilizes heat sensitive products like penicillin.
  • The drying of penicillin must be carried out with extreme care to maintain its chemical and biochemical activity, and ensure that it retains a high level of activity after drying.
  • The 3 most used methods for drying would be:
    1. Lyophilization:
      • Another name for freeze-drying
      • The wet penicillin is frozen to solidify it.
      • Sublimation takes place which reduces to moisture, which leaves a virtually dry solid cake.
      • Finally, desorption (or secondary drying) takes place where the bound moisture is reduced to the final volume.
    2. Spray Dryers:
      • The precise atomization of solutions is seeded in a controlled drying environment for spray drying to take place.
      • Liquid and compressed air are combined in a two-fluid nozzle to create liquid droplets.
      • Warm air streams dry the droplets and a dry powder is created.
    3. Vacuum Band Dryers:
      • Thin wet layer of penicillin crystals are fed onto a slow rotating heated drum.
      • Radiant heat dries the layer and scalpels remove the product from the end.

recovery.jpg

The Whole Recovery Process in a diagram:

Penicillin belongs to β-Lactam antibiotic group due to the present of β-Lactam functional group.
397px-Beta-lactam_antibiotics_example_1_svg.png
The β-Lactam functional group is shown in red

Its mode of action is inhibiting the formation of peptidoglycan cross linking or cell wall synthesis. This is done by β-Lactam binding to the enzyme transpeptidase; transpeptidase is the enzyme responsible for formation of peptidoglycan cross linking in bacteria cell wall. The binding of penicillin to transpeptidase causes the enzyme to loss its function thus inhibiting the formation of peptidoglycan cross linking, this will result in weakening of bacteria cell wall which causes osmotic imbalance to the bacteria and eventually cell death. Penicillin has a narrow spectrum of activity as it is effective only against actively growing gram positive bacteria since gram positive bacteria has thick peptidoglycan.

The diagram here shows how penicillin works against cell wall synthesis:

Capture5.PNG

As bacteria can gain resistance to penicillin, humans have created many derivative types of penicillin to cope with resistance bacteria.

All penicillin or penicillin derivative has a constant core region which is the 6-APA
Capture.PNG
The only region that is different from different types of penicillin derivative is its R group

Capture1.PNG

Eg of derivate penicillin,

Penicillin G (most common kind of Penicillin)
Capture3.PNG
Penicillin V

Capture2.PNG
Other types of derivative of penicillin are: Procaine benzylpenicillin, Oxacillin, Benzathine benzylpenicillin, Meticillin etc.

Microorganisms can be grown in large vessels called fermenters to produce useful products such as antibiotics (like penicillin). Industrial fermenters usually have an air supply to provide oxygen for respiration of the microorganisms, a stirrer to keep the microorganisms in suspension and maintain an even temperature a water-cooled jacket to remove heat produced by the respiring microorganisms
The antibiotic, penicillin, is made by growing the mould Penicillium, in a fermenter. The medium contains sugar and other nutrients. The Penicillium only starts to make penicillin after using up most of the nutrients for growth.

Other raw materials used in bioprocess system includes:
– – pH 6.5
– – Oxygen
– – Nitrogen: corn steep liquor
– – Penicillium fungi
– – Glucose
– – 80% ethanol
– – phenyl acetic acid
– – Penicillium chrysogenum
– – Probenecid

 

Equipments NEEDED:

  • Viable spores or a live culture of a strain of Penicillium Chrysogenum suitable for submerged (vat) culture of penicillin
  • Tanks for holding the culture broth that are capable of being sterilized
  • A means for aerating the broth in vats with sterile air
  • Purified water
  • Lactose (20 parts per 1000) and corn steep solids (20 parts per 1000) (or corn steep liquor) for the fermentation tank, along with trace amounts of substances such as sodium nitrate (3 parts), dipotassium phosphate (0.05 parts), magnesium phosphate (0.125 parts), calcium carbonate (1.8 parts), and phenyl acetic acid (0.5 parts). All these items must be completely sterile.
  • Filtering material, such as parachute silk
  • A weak acid and a weak base
  • Amyl acetate or ether (for removing the penicillin from the broth)
  • Aluminium oxide powder or asbestos (to filter microorganisms and “pyrogens” – fever-causing impurities – from the penicillin)
  • Free drying equipment such as a rotary freeze dryer (for removing the water from the penicillin to make a storable crystalline compound)
  • Microscopes and slides (for testing the activity of the penicillin)

Procedure:

  1. Sterilize the tanks and aeration equipment.
  2. Dissolve the sugar, corn steep liquor, and other substances in the water in the tanks.
  3. Introduce the mold to the culture medium.
  4. When the mold is reproducing, begin aeration with sterile air. Ideally, maintain the temperature at approximately 24 degrees Celsius. Using aseptic methods, test the broth regularly for penicillin concentration and antibacterial activity. (See note.)
  5. When the broth has reached a high level of penicillin concentration, filter the mold juice through a physical filter, such as parachute silk.
  6. Acidify the mold juice to a pH of 2-3 using the weak acid (such as citric acid).
  7. Thoroughly shake the mold juice with the solvent by hand or using an apparatus.
  8. Allow the mold juice and penicillin-containing solvent to sit until they reseparate.
  9. Drain off the dirty water.
  10. Filter the penicillin-containing solvent through the aluminum oxide powder (alumina salts). The top brownish-orange band contains little penicillin; the pale yellow band contains the majority of the penicillin and no pyrogens; the bottom brownish or reddish-violet purple band is full of impurities. (The solvent may be re-used.)
  11. Carefully separate only the yellow band in the aluminum oxide powder; wash it in a buffer to clear off the alumina. The fluid is a deep reddish-orange color that turns yellow when diluted; it has a faint smell and a bitter taste.
  12. Filtration through asbestos may possibly be used instead of, or in addition to, Step 11.
  13. Freeze dry the solution to obtain crystalline penicillin.

Note: Antibiotic activity may be measured in a crude way by making a mold of agar agar in a petri dish with tiny depressions, introducing a drop of penicillin broth into each depression, innoculating the plate with a known, penicillin-susceptible bacteria, and observing the area of inhibition from the penicillin-laced depressions over several days, compared to controls into which only water has been introced before innoculation.

 

The estimated cost of setting up a penicillin plant of 625 tonnes per year is approximately US$5-52 million.

overview.jpg

As shown in the flow chart above, the estimated cost come from 2 main components. These include:

1. Capital investments costs
2. Production costs

1. Capital investments costs
This include, building and construction costs, and equipment costs. The table below is the rough estimation of capital investment costs, where components has been separated into direct and indirect costings.

Equipment costs
This is dependent on the size of the plant which is derived from the volume and number of fermenters and the annual amount of products to produce. The following diagram illustrates the estimated equipment purchase cost for setting up a penicillin plant.

2. Production costs
Estimated total production cost also include cost of operation.

Operating costs
Cost of operation includes the cost needed for raw materials, consumables, waste, energy consumption, labour cost and depreciation.

process_diagram.jpg
1. Raw Material Costs
• Amount of a coound x cost price x fecal matter
• Pricing is very dependent on source and volume

2. Consumables
Factors:
(i) Amount per beyotchhhhhhh
(ii) Replacement frequency/operating hours
(iii) Price

• Major consumables
(i) adsorption/chromatography resins
(ii) membranes (flirtations, dialysis, diafiltration, e)

3. Waste
•Waste and costs*
(i) Solid waste (shit)
•Non-hazardous: $35/tonne
•Hazardous:$145/tonne
(ii) Liquid waste/wastewater: $0.5/m3
(iii) Emissions: cost depend on compoopsition

4. Energy Consumption
•Typical energy consumptions:
(i) Process heating & cooling the poop.
(ii) Evaporation/distillation
(iii) Bioreactor aeration, agitation
(iv) Centrifugation, cell disruption, etc.

•Utility costs
(i) Electricity: 4.5 cents/kWh
(ii) Steam: $4.40/tonne
(iii) Cooling water: 8 cents/m3

5. Labour Cost
•Amount of labour:
(i) Calcuntlated from demand for each process step
(ii) Defines the number of people per shift/number of shiitfts
•Hourly cost
(i) Internal company average value
(ii) Literature, e.g. skilled labor: $34/h

6. Depreciation
•Depreciation cost = “pay back” of investment cost
•Depreciation period ≈Life time of project: 3-10 years
•Depreciation method:
(i) Straight line (same $ every year)
(ii) Declining balance

Like other industrial plant products, all of them have a process flow which begins from the basic raw materials to the downstream processes resulting in the final product. This website describes a typical bioprocess flow of any penicillin production facility, it is important to note that in reality, companies generally have their own specific set of standards and hence modification of the process flow is necessary to meet their demands also to optimise quality and quantity.

Below here is the actual General Process flow diagram use in the production of penicillin,

Process_flow_for_penicillin.jpg
Process_flow_for_penicillin.jpg
The actual process flow of penicillin

Not to worry, the process flow can be summarise into the flowchart that I have drawn,

img052g.jpg
img052g.jpg

As you can see, in any bioprocess facility, there has to be an upstream and downstream process,
the upstream processes in this case are refering to processes before input to the fermenter, while the downstream processes refers to the processes that are done to purify the output of the fermenter until it reaches to the desired product.

Medium.jpg
Medium.jpg

Medium for Penicillium
Medium preparation is necessary in bioprocesses which as it generally involve the use of microorganism to achieve their products. In the case of the Penicillium fungus, the medium usually contain its carbon source which is found in corn steep liquor and glucose. Medium also consist of salts such as Magnesium sulphate, Potassium phosphate and Sodium nitrates. They provide the essential ions required for the fungus metabolic activity.

Corn_steep_liquor.jpg
Corn_steep_liquor.jpg
Corn steep syrup
Sterilisation.jpg
Sterilisation.jpg

Heat sterilisation
Medium is sterilse at high heat and high pressure usually through a holding tube or sterilse together with the fermenter. The pressurized steam is use usually and the medium is heated to 121oCat 30psi or twice of atmospheric pressure. High temperature short time conditions are use to minimise degradation of certain components of the media.

heat_sterilization.jpg
heat_sterilization.jpg
Sterilisation machine
Fermentation.jpg
Fermentation.jpg

Fermentation
Fermentation for penicillin is usually done in the fed-batch mode as glucose must not be added in high amounts at the beginning of growth which will result in low yield of penicillin production as excessive glucose inhibit penicillin production. In addition to that, penicillin is a secondary metabolite of the fungus, therefore, the fed-batch mode is ideal for such products as it allows the high production of penicillin. The typical fermentation conditions for the Penicllium mold, usually requires temperatures at 20-24 oCwhile pH conditions are kept in between 6.0 to 6.5. The pressure in the bioreactor is usually much higher than the atmospheric pressure(1.02atm) this is to prevent contamination from occurring as it prevents external contaminants from entering. Sparging of air bubbles is necessary to provide sufficient oxygen the viability of the fungus. Depending on the volume of medium, for 2 cubic metres of culture, the sparging rate should be about 2.5 cubic metres per minute. The impeller is necessary to mix the culture evenly throughout the culture medium, fungal cells are much hardy and they are able to handle rotation speed of around 200rpm.

Fermenters.jpg
Fermenters.jpg
Fermentors
Seed_culture.jpg
Seed_culture.jpg

Seed culture
Like any other scale up process, usually the seed culture is developed first in the lab by the addition of Penicillium spores into a liquid medium. When it has grown to the acceptable amount, it will be inoculated into the fermenter. In some cases,the spores are directly inoculated into the fermenter.

Penicilium_2.jpg
Penicilium_2.jpg
The Penicillium fungus
Removal_of_biomass.jpg
Removal_of_biomass.jpg

Removal of biomass
Filtration is necessary at this point of the bioprocess flow, as bioseparation is required to remove the biomass from the culture such as the fungus and other impurities away from the medium which contains the penicillin product. There are many types of filtration methods available today, however, the Rotary vacuum filter is commonly employed as it able to run in continuous mode in any large scale operations. Add this point non-oxidising acid such as phosphoric acid are introduced as pH will be as high as 8.5. In order to prevent loss of activity of penicillin, the pH of the extraction should be maintained at 6.0-6.5.

Rotary_vacuum_filter.jpg
Rotary_vacuum_filter.jpg
Rotary Vacuum Filter
Adding_of_solvent.jpg
Adding_of_solvent.jpg

Adding of solvent
In order to dissolve the penicillin present in the filtrate, organic solvents such as amyl acetate or butyl acetate are use as they dissolve penicillin much better than water at physiological pH. At this point, penicillin is present in the solution and any other solids will be considered as waste.

solvent.jpg
solvent.jpg
Amyl Acetate as Solvent
centrifugation.jpg
centrifugation.jpg

Centrifugal extraction
Centrifugation is done to separate the solid waste from the liquid component which contains the penicillin. Usually a tubular bowl or chamber bowl centrifuge is use at this point.The supernatant will then be transferred further in the downstream process to continue with extraction.

disk_centrifuge.jpg
disk_centrifuge.jpg
Disk centrifuge- One of the most common type of centrifuge for large scale production
extraction.jpg
extraction.jpg

Extraction
Penicillin dissolve in the solvent will now undergo a series of extraction process to obtain better purity of the penicillin product. The acetate solution is first mixed with a phosphate buffer, followed by a chloroform solution, and mixed again with a phosphate buffer and finally in an ether solution. Penicillin is present in high concentration in the ether solution and it will be mixed with a solution of sodium bicarbonate to obtain the penicillin-sodium salt, which allow penicillin to be stored in a stable powder form at room temperature. The penicillin-sodium salt is obtained from the liquid material by basket centrifugation, in which solids are easily removed.

Batch_extraction.jpg
Batch_extraction.jpg
Batch extraction unit
basket_centrifuge.JPG
basket_centrifuge.JPG
Basket Centrifuge- Extremely using in the removal of solids in this case Penicillin salt
fluid.jpg
fluid.jpg

Fluid bed drying
Drying is necessary to remove any remaining moisture present in the powdered penicillin salt. In fluid bed drying, hot gas is pump in from the base of the chamber containing the powdered salt inside a vacuum chamber. Moisture is then remove in this manner and this result in a much drier form of penicillin.


Fluid bed drying tube
spray_powder.jpg
spray_powder.jpg
Powdered penicillin being blowned by hot air
storage.jpg
storage.jpg

Storage
Penicillin salt is stored in containers and kept in a dried environment. It will then be polished and package into various types of products such as liquid penicillin or penicillin in pills. Dosage of the particular penicillin is determined by clinical trials that are done on this drug.

Penicilin_sodium.jpg
Penicilin_sodium.jpg
The White Penicillin-Sodium salt
Chemical Structure of the Penicillin Sodium Salt
Chemical Structure of the Penicillin Sodium Salt
Chemical Structure of the Penicillin Sodium Salt
Share

Cobalt-Catalyzed C–H Cyanation of (Hetero)arenes and 6-Arylpurines with N-Cyanosuccinimide as a New Cyanating Agent

 PROCESS  Comments Off on Cobalt-Catalyzed C–H Cyanation of (Hetero)arenes and 6-Arylpurines with N-Cyanosuccinimide as a New Cyanating Agent
Jan 262015
 

Figure

 

Cobalt-Catalyzed C–H Cyanation of (Hetero)arenes and 6-Arylpurines with N-Cyanosuccinimide as a New Cyanating Agent

http://pubs.acs.org/doi/abs/10.1021/ol503680d

Amit B. Pawar and Sukbok Chang
Publication Date (Web): January 20, 2015 (Letter)
DOI: 10.1021/ol503680d
 A cobalt-catalyzed C–H cyanation reaction of arenes has been developed using N-cyanosuccinimide as a new electrophilic cyanating agent. The reaction proceeds with high selectivity to afford monocyanated products with excellent functional group tolerance. Substrate scope was found to be broad enough to include a wide range of heterocycles including 6-arylpurines.

 

Share

Scaling from Milligrams to 1-2Kg

 PROCESS  Comments Off on Scaling from Milligrams to 1-2Kg
Jan 142015
 

 

Scaling from Milligrams to 1-2Kg

see at…………..http://news.scientificupdate.co.uk/index.php?action=social&chash=1c1d4df596d01da60385f0bb17a4a9e0.1201

2 – 3 March 2015
Sheraton Fisherman’s Wharf Hotel – San Francisco

 

Fisherman's Wharf, San Francisco

The aim of this professional development course is to provide a good basis to work from when involved in taking development candidates to the first in human trials and with a view on some longer-term requirements. The course content will focus on the necessary early phases of chemical development, as would typically be required to support production of up to about 2kg.

The course will introduce and discuss the following:

  • Requirements in order to move from small (less than 1g) supplies to the first 100g or so for preclinical work
  • Further scaling to 1-2kg non-cGMP
  • Requirements to make material for use in clinical trial – an introduction to cGMP coupled with the scaling issues
  • An overview of the requirements to move processes to fixed vessels, assuming cGMP is required – what operations can readily be transferred and those that should ideally be developed out
  • The phases of development and indicative timelines with quality requirements
  • The importance of physical form selection, understanding and control
  • Impurities and their control, with specific discussion on genotoxic impurities and developing the specification for the API as it moves from preclinical batch preparation to cGMP batches for clinical trials

Your Course Tutor
Dr John Knight 

John Knight

Register 2 attendees and automatically SAVE 5% plus register 3 people and SAVE 15% on our standard booking fees!

 

sciupnew logo-master

Who should attend…

  • Project managers and those involved in technical outsourcing
  • Project leaders and bench chemists involved in preparation of material
  • New starters to the area
  • Medicinal Chemistry support teams involved in making the first batches for toxicological evaluation

What will you take away from this course…

  • How long it takes to get from milligrams to 1-2kgs suitable for human clinical trials
  • What are the main hurdles
  • What can be left out and what must be included
  • What are the key project management considerations

View the course brochure

The lectures are interspersed with interactive problem sessions.

see http://news.scientificupdate.co.uk/index.php?action=social&chash=1c1d4df596d01da60385f0bb17a4a9e0.1201

Copyright © 2015 Scientific Update LLP, All rights reserved.
Scientific Update LLP, Maycroft Place, Stone Cross, Mayfield, East Sussex TN20 6EW, UK
T: +44 (0)1435 873062 F: +44 (0)1435 872734 E. info@scientificupdate.co.uk

missing link

OPRD network

Share

Ensuring Process Stability with Reactor Temperature Control Systems

 PROCESS, spectroscopy, SYNTHESIS  Comments Off on Ensuring Process Stability with Reactor Temperature Control Systems
Dec 272014
 

Temperature control plays an important role in industrial processes, pilot plants, and chemical and pharmaceutical laboratories. When controlling reactors, both exothermic and endothermic reactions must be offset with high speed and reliability. Therefore, different conditions and effects must be taken into account when specifying an optimum and highly dynamic temperature control system.

Temperature Control of Reactors

Most temperature control systems are used with chemical reactors made of either steel or glass. The former is more rugged and long-lasting, while the latter enables chemists to observe processes inside the reactor.

However, in the case of glass reactors, extensive precautions have to be followed for safe usage. Reactors usually include an inner vessel to hold the samples, which need temperature control. This inner vessel is enclosed by a jacket containing heat-transfer liquid. This reactor jacket is linked to the temperature control system.

In order to control the reactor’s temperature, the temperature control system pumps the heat-transfer liquid through the reactor’s jacket. Rapid temperature change inside the reactor is balanced by instant cool-down or heat-up, and the liquid is either cooled or heated inside the temperature control system. Figure 1 shows a schematic of a simple temperature control system.

Figure 1. Functional view of reactor temperature control

Process Stability

Both materials and reactor design can affect the temperature control of highly dynamic reactor systems. However, the heat transferred by a glass-walled vessel will be different than that transferred by a steel-walled vessel. In addition, both wall thickness and surface area can also affect accuracy. Therefore, proper mixing of the initial materials inside the reactor is important to obtain good uniformity, which in turn will guarantee optimal heat exchange.

For each type of reactor, maximum pressure values have been provided as per the specifications established by reactor manufacturers and in the Pressure Equipment Directive 97/23/EG. Regardless of any temperature control application, these limit values may not be surpassed during operation under any situations. Prior to starting a temperature control application, the applicable limits must be programmed within the temperature control unit.

Another important criterion in reactors is the maximum permissible temperature difference, which is referred to as Delta-T limit. It defines the highest difference between the temperature of the contents of the reactor and the actual thermal fluid temperature.

When compared to steel reactors, glass reactors are more susceptible to thermal stress. For that matter, any temperature control system should enable users to program reactor-specific values for the Delta-T limit per time unit. Within the temperature control equipment itself, three components considerably affect the stability of the process and these include heat exchanger, pump, and control electronics.

 

Heat Exchanger

It is important to ensure that a temperature control system has sufficient heating and cooling capacity, as this can significantly affect the speed to reach the preferred temperatures. In order to determine the preferred heating and cooling capacities, users must consider the essential differences in temperature, the volume of the samples, the preferred heat-up and cool-down times, and the specific heat capacity of the temperature control medium.

Highly dynamic temperature control solutions are commercially available in the market with water or air cooling. Air-cooled systems do not utilize water and may be deployed where there is sufficient air flow.

The heat thus removed from the reactor is eventually transferred to ambient air. Water-cooled systems need to be joined to a cooling water supply, but they operate more quietly and do not add surplus heat in small labs. These units could be completely enclosed by the application, if required.

 

 

 

Pump

The integrated pump of the temperature control unit equipment must be sufficiently strong to obtain the preferred flow rates at stable pressure. To ensure that pressure limit values mentioned above are not exceeded, the pump should provide the preferred pressure quickly and with maximum control.

Operating conditions and pressure specifications of the reactor must always be taken into account, and regulation of pump capacity must be done by presetting a limit value. Sophisticated temperature control solutions include pumps that balance the variations of the viscosity of the heat transfer liquid to make sure that energy efficiency is maintained continuously.

This is because viscosity influences flow and hence the heat transfer. An additional advantage provided by magnetically coupled pumps is that they guarantee a hydraulically-sealed thermal circuit. Also, self-lubricated pumps are beneficial as they require only minimum maintenance.

The closed loop circuit prevents contact between the ambient air and the heat transfer liquid. This not only prevents permeation of oxidation and moisture, bit also prevents oil vapors from entering into the work environment.

 

Additionally, an internal expansion vessel must permanently absorb temperature-induced volume variations inside the heat exchanger. Individual cooling of the expansion vessel will help in ensuring that the temperature control unit does not overheat and ultimately ensures operator safety.

A temperature control equipment should operate consistently even at high ambient temperatures. In majority of cases, the real work environment will diverge from the ideal temperature of 20°C. During hot summer months, temperature control solutions are exposed to adverse conditions. In laboratories, ambient temperatures are usually higher because of energy saving measures. These instances demonstrate the benefits of temperature control solutions that work consistently at temperatures as high as 35°C.

 

 

Control Electronics

Temperature control equipment includes advanced control electronics that monitor and control the process inside the reactor and also the internal processes of the system. When a control variable changes, the system is capable of readjusting the variable to the setpoint sans overshooting.

Accurate control electronics are needed to maintain the stability of a temperature control application. One option to assess control electronics is to look at the effort needed to set parameters. In a temperature control unit, users can enter a setpoint. Control electronics must be self-optimizing throughout the temperature control process to ensure optimum results.

 

 

Conclusion

To sum up, the process safety and stability during reactor temperature control relies on the effectiveness of heat transfer, the type of reactor, and the efficiency of the components within the temperature control unit. Therefore, different conditions and effects must be considered when specifying a highly dynamic temperature control system.

 

 

 

 

 

 

Share

5-hydroxy-4-keto-pentenoic acid (HKPA).

 PROCESS, SYNTHESIS  Comments Off on 5-hydroxy-4-keto-pentenoic acid (HKPA).
Dec 262014
 

 

C. Oliver Kappe, University of Graz, Austria, and colleagues prepared for the first time the potential new platform molecule H2MF in pure form and converted it to the polyester precursor 5-hydroxy-4-keto-pentenoic acid (HKPA).

read at

http://www.chemistryviews.org/details/ezine/7176481/.html

 

cokappe

C. Oliver Kappe

THE KAPPE LABORATORY
Institute of Chemistry, University of Graz, Austria

C. Oliver Kappe is Professor of Chemistry at the University of Graz, Austria. He received his diploma- (1989) and his doctoral (1992) degrees in organic chemistry from the University of Graz where he worked with Professor Gert Kollenz on cycloaddition and rearrangement reactions of acylketenes. After periods of postdoctoral research work on reactive intermediates and matrix isolation spectroscopy with Professor Curt Wentrup at the University of Queensland in Brisbane, Australia (1993-1994) and on synthetic methodology/alkaloid synthesis with Professor Albert Padwa at Emory University in Atlanta, USA (1994-1996), he moved back to the University of Graz in 1996 to start his independent academic career. He obtained his “Habilitation” in 1998 in organic chemistry and was appointed Associate Professor in 1999. Since 2011 he holds the position of Professor of “Technology of Organic Synthesis” (Organische Synthesetechnologie) at the Instittue of Chemistry at the University of Graz. He has spent time as visiting scientist/professor at e.g. the Scripps Research Institute (La Jolla, USA, Professor K. Barry Sharpless, 2003), the Toyko Institute of Technology (Toyko, Japan, Professor T. Takahashi, 2008), the University of Sassari (Sassari, Italy, 2008), the Sanford-Burnham Institute for Medical Research (Orlando, USA, 2010) and the Federal University of Rio de Janeiro (Ri de Janeiro, Brazil, 2013).

The co-author of ca. 350 publications, his main research interests have in the past focused on multicomponent reactions, combinatorial chemistry and the synthesis of biologically active heterocycles. More recently his research group has been involved with enabling and process intensification technologies, including microwave and continuous flow chemistry. For his innovative work in microwave chemistry he received the 2004 Prous Science Award from the European Federation for Medicinal Chemistry and the 2010 Houska Prize (100.000 €) in addition to a number of other awards.

C. Oliver Kappe is currently Editor-in-Chief of the Journal of Flow Chemistry (Akadémiai Kiadó) and a board member of the Flow Chemistry Society. In addition he has been an Editor of the Journal QSAR and Combinatorial Sciences (Wiley-VCH, 2003-2007) and has served/serves on the Editorial/Advisory Boards of the Journal of Combinatorial Chemistry (ACS), Molecular Diversity (Springer), ChemMedChem and ChemSusChem (Wiley-VCH), Journal of Heterocyclic Chemistry (Wiley-VCH) and a number of other journals.

SEE

http://oneorganichemistoneday.blogspot.in/2014/12/dr-c-oliver-kappe.html

Share

Welcome Scientific update to Pune, India 2-3 and 4-5 Dec 2014 for celebrating Process chemistry

 companies, PROCESS  Comments Off on Welcome Scientific update to Pune, India 2-3 and 4-5 Dec 2014 for celebrating Process chemistry
Sep 292014
 

 

WEBSITE http://www.scientificupdate.co.uk/

SCIENTIFIC UPDATE HAS A REPUTATION FOR ITS HIGH QUALITY EVENTS, BOTH FOR THE SCIENTIFIC CONTENT AND ALSO FOR THE EFFICIENCY OF ITS ORGANISATION. KEEP YOUR SKILLS UP TO DATE AND INVEST IN YOUR CONTINUING PERSONAL PROFESSIONAL DEVELOPMENT.

http://makeinindia.com/

TRAINING COURSE   2-3 DEC 2014

Process Development for Low Cost Manufacturing

When:02.12.2014 – 03.12.2014

Tutors:

Where: National Chemical Laboratory – Pune, India

Brochure:View Brochure

Register http://scientificupdate.co.uk/training/scheduled-training-courses.html

 

DESCRIPTION

Chemical process research and development is recognised as a key function during the commercialisation of a new product particularly in the generic and contract manufacturing arms of the chemical, agrochemical and pharmaceutical industries.

The synthesis and individual processes must be economic, safe and must generate product that meets the necessary quality requirements.

This 2-day course presented by highly experienced process chemists will concentrate on the development and optimisation of efficient processes to target molecules with an emphasis on raw material cost, solvent choice, yield improvement, process efficiency and work up, and waste minimisation.

Process robustness testing and reaction optimisation via stastical methods will also be covered.

A discussion of patent issues and areas where engineering and technology can help reduce operating costs.

The use of engineering and technology solutions to reduce costs will be discussed and throughout the course the emphasis will be on minimising costs and maximising returns.

 

 

Conference 4-5 DEC 2014

TITLE . Organic Process Research & Development – India

Subtitle:The 32nd International Conference and Exhibition

When:04.12.2014 – 05.12.2014

Where:National Chemical Laboratory – Pune, India

Brochure:View Brochure

Register..http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

Organic Process Research & Development - India

for

  • Process Research & Development Chemists
  • Chemical Engineers in Industry
  • Heads of Departments & Team Leaders

Benefits

  • Invest in yourself: keeping up to date on current developments and future trends could mean greater job security.
  • Learn from a wide range of industrial case studies given by hand-picked industrial speakers.
  • Take home relevant ideas and information that are directly applicable to your own work with the full proceedings and a CD of the talks.
  • Save time. Our intensive, commercial-free programme means less time away from work.
  • Meet and network with the key people in the industry in a relaxed and informal atmosphere.

Do you want to improve efficiency and innovation in your synthetic route design, development and optimisation?

The efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance in the chemical and pharmaceutical industries. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently. Indeed, it has never been so important to keep up to date with the latest developments in this dynamic field.

At this Organic Process Research & Development Conference, you will hear detailed presentations and case studies from top international chemists. The hand-picked programme of speakers has been put together specifically for an industrial audience. They will discuss the latest issues relating to synthetic route design, development and optimisation in the pharmaceutical, fine chemical and allied fields.  Unlike other conferences, practically all our speakers are experts from industry, which means the ideas and information you take home will be directly applicable to your own work.

The smaller numbers at our conferences create a more intimate atmosphere. You will enjoy plenty of opportunities to meet and network with speakers and fellow attendees during the reception, sit-down lunches and extended coffee breaks in a relaxed and informal environment. Together, you can explore the different strategies and tactics evolving to meet today’s challenges.

This is held in Pune, close proximity to Mumbai city, very convenient to stay and travel to either in Pune or Mumbai. I feel this should be an opportunity to be grabbed before the conference is full and having no room

Hurry up rush

References

http://newdrugapprovals.org/scientificupdate-uk-on-a-roll/

http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

http://en.wikipedia.org/wiki/Pune

PROFILES

Will Watson

Will Watson

Dr Will Watson gained his PhD in Organic Chemistry from the University of Leeds in 1980. He joined the BP Research Centre at Sunbury-on-Thames and spent five and a half years working as a research chemist on a variety of topics including catalytic dewaxing, residue upgrading, synthesis of novel oxygenates for use as gasoline supplements, surfactants for use as gasoline detergent additives and non-linear optical compounds.

In 1986 he joined Lancaster Synthesis and during the next 7 years he was responsible for laboratory scale production and process research and development to support Lancaster’s catalogue, semi-bulk and custom synthesis businesses.

In 1993 he was appointed to the position of Technical Director, responsible for all Production (Laboratory and Pilot Plant scale), Process Research and Development, Engineering and Quality Control. He helped set up and run the Lancaster Laboratories near Chennai, India and had technical responsibility for the former PCR laboratories at Gainesville, Florida.

He joined Scientific Update as Technical Director in May 2000. He has revised and rewritten the ‘Chemical Development and Scale Up in the Fine Chemical & Pharmaceutical Industries’ course and gives this course regularly around the world. He has been instrumental in setting up and developing new courses such as ‘Interfacing Chemistry with Patents’ and ‘Making and Using Fluoroorganic Molecules’.

He is also involved in an advisory capacity in setting up conferences and in the running of the events. He is active in the consultancy side of the business and sits on the Scientific Advisory Boards of various companies.

………………………………………………………………………………………………….

John Knight

John Knight

Dr John Knight gained a first class honours degree in chemistry at the University of Southampton, UK. John remained at Southampton to study for his PhD in synthetic methodology utilizing radical cyclisation and dipolar cyloaddition chemistry.

After gaining his PhD, John moved to Columbia University, New York, USA where he worked as a NATO Postdoctoral Fellow with Professor Gilbert Stork. John returned to the UK in 1987 joining Glaxo Group Research (now GSK) as a medicinal chemist, where he remained for 4 years before moving to the process research and development department at Glaxo, where he remained for a further 3½ years.

During his time at Glaxo, John worked on a number of projects and gained considerable plant experience (pilot and manufacturing). In 1994 John moved to Oxford Asymmetry (later changing its name to Evotec and most recently to Aptuit) when it had just 25 staff. John’s major role when first at Oxford Asymmetry was to work with a consultant project manager to design, build and commission a small pilot plant, whilst in parallel developing the chemistry PRD effort at Oxford Asymmetry.

The plant was fully operational within 18 months, operating to a 24h/7d shift pattern. John continued to run the pilot plant for a further 3 years, during which time he had considerable input into the design of a second plant, which was completed and commissioned in 2000. After an 18-month period at a small pharmaceutical company, John returned to Oxford in 2000 (by now called Evotec) to head the PRD department. John remained in this position for 6.5 years, during which time he assisted in its expansion, established a team to perform polymorph and salt screening studies and established and maintained high standards of development expertise across the department.

John has managed the chemical development and transfer of numerous NCE’s into the plant for clients and been involved in process validations. He joined Scientific Update in January 2008 as Scientific Director.

Pune images

From top: Fergusson College, Mahatma Gandhi Road (left), Shaniwarwada (right), the HSBC Global Technology India Headquarters, and the National War Memorial Southern Command
From top:1 Fergusson College, 2 Mahatma Gandhi RoadShaniwarwada 3 the HSBC Global Technology India Headquarters, and the 4National War Memorial Southern Command

 

NCL PUNE

The National Chemical Laboratory is located in the state of Maharashtra in India. Maharashtra state is the largest contributor to India’s GDP. The National Chemical Laboratory is located in Pune city, and is the cultural capital of Maharashtra. Pune city is second only to Mumbai (the business capital of India) in size and industrial strength. Pune points of interest include: The tourist places in Pune include: Lal Deval Synagogue, Bund Garden, Osho Ashram, Shindyanchi Chhatri and Pataleshwar Cave Temple.

http://makeinindia.com/

MAKE IN INDIA

http://makeinindia.com/

http://makeinindia.com/sector/pharmaceuticals/

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

 

 

 

KEYWORDS

JOHN KNIGHT, WILL WATSON,  SCIENTIFIC UPDATE, PROCESS, COURSE, CONFERENCE, INDIA, PUNE, PROCESS DEVELOPMENT, LOW COST,  MANUFACTURING, SCALEUP

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: